TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients with major vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum concentration of anti-hinge region antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intracranial Objective Response Rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Movement times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival Rate at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of new atrial fibrillation paroxysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dietary fat, fruits & vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of E2022 patch compared to E2020 tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global left ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global right ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lateralization of Frontal Lobe Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Revision arthroplasty due to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Primary permeability maintenance of the iliac branch endoprosthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Successful drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procedure-related complication
Endpoint domain: Adverse events/effects
Primary endpoint: MAFbx mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of renal glomerular function and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Markers of renal tubular function and damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PaCO2 levels at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in natural killer cell cytotoxicity (NKCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of chemoradiation-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in participant reports of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Emotional Numbing Symptoms of PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Observed Blood Concentration at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Reach Maximum Observed Blood Concentration at Steady State (Tmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Blood Trough Concentration at Steady State (Ctrough,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Serum Uric Acid Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper Limb Neural Tension Test R2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Neural Tension Test P2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervico-Thoracic Spine Lateral Bending
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom of atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total procedural contrast fluid use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in plasma Amino Acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Dietary intake of Phenylalanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in liver iron stores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: development of iron overload-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of diagnosis Agreement in IFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortisol awakening response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in resting systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in depression, anxiety and stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain-relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Total IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minor and major periprocedural morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: ED50 in intravenous cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of breast cancer in women with pre- and per-gravidic exposure
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: TXA plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Earlier Healing of the Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection rate for nuchal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: detection rate of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of forced expiratory volume in 1 second (FEV1) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dexmedetomidine serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time investment by HF nurses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Metal Ion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appearance score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convenience score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Successful bowel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of unacceptable adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in composite score of cancer prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gait Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline choroidal thicknesses at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pupil diameter sizes at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neuropathic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Value-behavior discrepancy for values related to alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ-C) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of anal high risk HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute oral bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic characteristics of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ranges of motion in six-degree-of-motion (6DOF) of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Signs and symptoms of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of sleepwalking episodes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Variability of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence and severity of Flu Like Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence and severity of Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Late RTOG radiotherapy toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants In Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuropsychological performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective Image Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Questionnaire of FoG (FoG-Q)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantitative evaluation of FoG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mammographic density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Rabies Virus Neutralizing Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rotational stability of IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to intraabdominal high ligation of inguinal hernia
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: reduction in hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with any serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with any hemorrhagic adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or absence of reoccurrence of VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Carotenoids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Likert scale agreement with Perceived severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Likert scale agreement with Perceived susceptibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Likert scale agreement with Perceived barriers to change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Likert scale agreement with self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Likert scale agreement with Outcome efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Non-attendance rate of colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: annual change of GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: annual change of Ccr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence rate of the doubling of sCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adverse events related to CC-90003
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of CC-90003
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) observed maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of pain and discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of neuromuscular function at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants with Serious and Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cognitive Function Scores - HVLT and COWA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive Function Scores - Color Trails 1 & 2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive Function Scores - Digit Span
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Cognitive Function Scores - Symbol Digit Modalities Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rib fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of organoid formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Established PDX histologically
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Established PDX genetically
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean score of the MQLI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mobility Diaphragmatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relative change in plasma IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of myofascial trigger point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of end-expiratory lung impedance (dEELI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infusion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PaO2 AUC from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in CGI-BP-OS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving Undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of post-mastectomy chronic pain syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of precocious puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dry mouth sensation relief change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of imipenem in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Cardiac and Liver Iron Overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Siderosis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Incontinence-Associated Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Category of Incontinence-Associated Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erosion healing percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of the CA4P-paclitaxel-carboplatin combination
Endpoint domain: Adverse events/effects
Primary endpoint: change in tumor blood flow by use of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in inflammatory markers in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fat flavor intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat flavor hedonic value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Integrated Bayesian Information Criterion (BIC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Schiff Sensitivity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Tactile Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Sensitive Teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: ARC-defined stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding defined according to BARC classification
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events in Part 2
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: DLT Of Botensilimab
Endpoint domain: Adverse events/effects
Primary endpoint: RP2D Of Botensilimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of biotin deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: area under the plasma concentration time curve from time zero to the last quantifiable time points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum observed concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3 and 4 acute GVHD cortico-resistant
Endpoint domain: Adverse events/effects
Primary endpoint: MADRS (Montgomery-Åsberg Depression Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TGF-beta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Time-weighted Average Over 24 Hours Post Dose in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Time-weighted Average Over 24 Hours Post Dose in Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Urine Sodium at 24 Hours Post-dose on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of men adopting Active Surveillance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical improvement Vancouver score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of subjects with confirmed postdose positive anti-pegfilgrastim antibody test result
Endpoint domain: Adverse events/effects
Primary endpoint: Children's hemoglobin status at 4 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Children's iron status at 4 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composition of milk in terms of fatty acids (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Palatability of oral prednisone formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CSSRS Suicidal Behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Rehospitalization with Suicidal Ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Neurotoxicity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of first consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention